Oral Agents for Type 2 Diabetes: An Update
- Bonnie Kimmel, MD and
- Silvio E. Inzucchi, MD
Abstract
IN BRIEF
The paradigms for oral pharmacological therapy in type 2 diabetes are shifting as we attain new insights into the optimal metabolic control in our patients. Each drug category has unique advantages and disadvantages, and their proper use necessitates a full understanding of their mechanisms of action, glycemic and nonglycemic effects, and prescribing indications. This article reviews published clinical trial data and places them into the context of contemporary, rational therapeutic strategies for this increasingly common condition.
Footnotes
-
Bonnie Kimmel, MD, is a senior resident in general internal medicine at the Yale Primary Care Residency Program in Waterbury and New Haven, Conn. Silvio E. Inzucchi, MD, is a professor of medicine and clinical director of the Section of Endocrinology at Yale University School of Medicine and director of the Yale Diabetes Center at Yale-New Haven Hospital in New Haven, Conn.
-
Note of disclosure: Dr. Inzucchi has served on advisory boards for Takeda, Pfizer, and Novartis. He has received honoraria for speaking engagements from Takeda, GlaxoSmithKline, and Bristol-Myers Squibb. These companies market oral pharmaceutical products for the treatment of diabetes.
- American Diabetes Association
